SOLAR-PROMOTION
Climate-neutral power generation from solar and wind will place several new challenges on the energy system. Key is that a significantly higher degree of flexibility will be required compared to today to keep supply and consumption in balance. Flexible consumers can make a significant contribution to this. How this can be achieved will be an important topic at EM-Power Europe, the international trade fair for energy management and integrated energy solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515343343/en/
EM-Power Europe 2024 presents a wide range of solutions for more digitalization and flexibility. (Photo: Solar Promotion GmbH)
"According to EU calculations, the demand for flexibility will increase by 133 percent between now and 2030," explains Michael Villa, Managing Director of the European industry association smartEn. In a recent study, Agora Energiewende came to the conclusion that by 2035, electric cars, heat pumps and home storage systems will be able to shift around ten percent of the annual electricity demand required in Germany. That would accumulate to around 100 terawatt hours. This flexibility on the consumer side will save the economy around 4.8 billion euros. But how can consumers make contributions to the energy transition?
Making ideal use of your own electricity
An initial consumer contribution to flexibilization has been a proven state of the art for years: prosumers with their own photovoltaic system linked to a stationary battery storage system, their own heat pump and charge their electric car with the electricity they generate themselves. This way, they not only minimize their own electricity consumption from the grid - they also reduce the load on the respective distribution grid by maximizing their own consumption.
Supply and demand
When there is a lot of electricity available from the sun and wind, prices on the European trading platform EEX fall. From 2025, all electricity suppliers in Germany will be obliged to offer their customers dynamic tariffs. They will then be able to optimize their consumption in terms of price. However, if many households consume a lot of electricity at the same time, the distribution grids will be under considerable strain. Making grid charges more flexible could counteract this effect: from 2025, grid charges in Germany will be higher at times of high grid utilization and lower at times of low utilization.
Suppliers intervene
Suppliers will also contribute to flexibility to a greater extent: if grid capacity threatens to become scarce, they can reduce their customers' consumption. This is an example that has been successfully practiced: If a bottleneck becomes apparent, suppliers can temporarily switch off connected heat pumps themselves. However, customers do not suffer any loss of comfort as a result, as thermal storage units keep their homes warm. In return, they receive the electricity for their heat pump at a particularly favorable price.
New: throttling instead of switching off
A novelty to the Energy Industry Act (EnWG) allows grid operators to throttle some wallboxes and heat pumps if there is a risk of grid overload. In return, grid operators may no longer refuse to connect such consumers on the grounds of possible grid overload.
EM-Power Europe
EM-Power Europe is the international trade fair for energy management and integrated energy solutions. Under the motto "Empowering Grids and Prosumers", it brings together stakeholders and focuses on current trends and developments. EM-Power Europe will take place from June 19 to 21, 2024 at Messe München.
Further information: www.em-power.eu
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515343343/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom